AZD1480
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis (PMF)
Conditions
Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
Trial Timeline
May 1, 2009 → Aug 1, 2014
NCT ID
NCT00910728About AZD1480
AZD1480 is a phase 1 stage product being developed by AstraZeneca for Primary Myelofibrosis (PMF). The current trial status is completed. This product is registered under clinical trial identifier NCT00910728. Target conditions include Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01112397 | Phase 1 | Terminated |
| NCT00910728 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Myelofibrosis (PMF)